95% patients recover from COVID-19 in five days after receiving Sotrovimab: Bahrain Health Ministry

TDT | Manama

The Daily Tribune – www.newsofbahrain.com

The Health Ministry has revealed that the treatment of COVID-19 infections with the use of monoclonal antibody drug “Sotrovimab” has proved effective.

The drug has been used since June 18 for COVID-19 patients in the Kingdom of Bahrain after the National Health Regulatory Authority (NHRA) approved it.

According to Ministry records, 95% of the patients recovered from the virus within five days only after receiving the drug, and that 100% of them left the hospital.

The Ministry also confirmed that all 230 patients who received the drug between 18 June and 1 July did not show any complications, and none of them was admitted to the intensive care unit.

There were no side effects of either of the drugs in all cases, the Ministry noted.

NHRA last month approved Sotrovimab for emergency use.

It is a new drug by GlaxoSmithKline (GSK) for the treatment of COVID-19. The decision to add Sotrovimab to COVID-19 treatment protocols followed emergency use approval by the US Food and Drug Administration (FDA) as well as a comprehensive review of GSK’s clinical trials.

Sotrovimab-VIR-7831 develops “monoclonal antibodies” to treat infected adults and adolescents with mild to moderate COVID-19 symptoms resulting in hospitalisation.

In a number of countries, Sotrovimab’s safety and efficacy evidence show a reduction in the number of cases requiring hospitalisation for more than 24 hours and a reduction in the number of fatalities by 85%, when administered at an early stage of treatment.